CitEc
[home]     [Citation data for:  series | authors | papers]      [Maintainers]      [Submit references]      [warning | faq | about]
  Updated Jun, 1 2012 364.619 documents processed, 8.178.370 references and 3.213.942 citations

 

  
 

PharmacoEconomics / Springer Healthcare | Adis

Raw citation data, Main indicators, Most cited papers , cites used to compute the impact factor (2010), Recent citations and documents published in this series in EconPapers.

Create citation feed for this series

Missing citations? Add them with our user input service
Incorrect content? Let us know

Raw data:
IF AIF DOC CIT D2Y C2Y SC(%) CiY II AII
19900.090000.04
19910.090000.05
19920.080000.04
19930.090000.05
19940.10000.05
19950.120000.06
19960.160000.08
19970.210000.08
19980.220000.09
19990.280000.13
20000.3710000.16
20010.380100.16
20020.410100.2
20030.430000.2
20040.4910000.22
20050.5220100.24
20060.510300.23
20070.4220300.19
20080.4320300.21
20090.43593400.19
20100.020.3696661100.15
 
 
IF: Impact Factor: C2Y / D2Y
AIF: Average Impact Factor for series in RePEc in year y
DOC: Number of documents published in year y
CIT: Number of citations to the series in year y
D2Y: Number of articles published in y-1 plus y-2
C2Y: Cites in y to articles published in y-1 plus y-2
SC(%): Percentage of selft citations in y to articles published in y-1 plus y-2
CiY: Cites in year y to documents published in year y
IdI: Immediacy Index: CiY / Documents.
AII: Average Immediacy Index for series in RePEc in year y

 

Main indicators

Most cited documents in this series:
YearTitleCited

RePEc:wkh:phecon:v:13:y:1998:i:3:p:293-304 [Citation Analysis]		15

RePEc:wkh:phecon:v:17:y:2000:i:5:p:461-477 [Citation Analysis]		4

RePEc:wkh:phecon:v:17:y:2000:i:5:p:501-513 [Citation Analysis]		3

RePEc:wkh:phecon:v:22:y:2004:i:13:p:857-876 [Citation Analysis]		3
2010Impact of European Pharmaceutical Price Regulation on Generic Price Competition: A Review
RePEc:wkh:phecon:v:28:y:2010:i:8:p:649-663 [Citation Analysis]		3

RePEc:wkh:phecon:v:24:y:2006:i:4:p:401-414 [Citation Analysis]		2

RePEc:wkh:phecon:v:23:y:2005:i:6:p:529-536 [Citation Analysis]		2

RePEc:wkh:phecon:v:21:y:2003:i:1:p:39-48 [Citation Analysis]		2

RePEc:wkh:phecon:v:15:y:1999:i:3:p:291-303 [Citation Analysis]		2

RePEc:wkh:phecon:v:23:y:2005:i:2:p:105-111 [Citation Analysis]		2

RePEc:wkh:phecon:v:20:y:2002:i:4:p:257-265 [Citation Analysis]		2

RePEc:wkh:phecon:v:13:y:1998:i:5:p:563-569 [Citation Analysis]		1

RePEc:wkh:phecon:v:23:y:2005:i:1:p:77-91 [Citation Analysis]		1

RePEc:wkh:phecon:v:25:y:2007:i:6:p:443-454 [Citation Analysis]		1
2010Time for Cooperation in Health Economics among the Modelling Community
RePEc:wkh:phecon:v:28:y:2010:i:8:p:609-613 [Citation Analysis]		1

RePEc:wkh:phecon:v:19:y:2001:i:11:p:1103-1109 [Citation Analysis]		1

RePEc:wkh:phecon:v:24:y:2006:i:11:p:1055-1068 [Citation Analysis]		1
2009Budget-Impact Analyses: A Critical Review of Published Studies
RePEc:wkh:phecon:v:27:y:2009:i:10:p:807-827 [Citation Analysis]		1

RePEc:wkh:phecon:v:22:y:2004:i:17:p:1097-1107 [Citation Analysis]		1

RePEc:wkh:phecon:v:24:y:2006:i:8:p:797-814 [Citation Analysis]		1
2010The Economics of Comparative Effectiveness Studies: Societal and Private Perspectives and their Implications for Prioritizing Public Investments in Comparative Effectiveness Research
RePEc:wkh:phecon:v:28:y:2010:i:10:p:843-853 [Citation Analysis]		1

RePEc:wkh:phecon:v:23:y:2005:i:7:p:651-658 [Citation Analysis]		1

RePEc:wkh:phecon:v:26:y:2008:i:9:p:781-798 [Citation Analysis]		1

RePEc:wkh:phecon:v:13:y:1998:i:1-part-2:p:127-134 [Citation Analysis]		1
2010Using Comparative Effectiveness Research to Inform Policy and Practice in the UK NHS: Past, Present and Future
RePEc:wkh:phecon:v:28:y:2010:i:10:p:799-811 [Citation Analysis]		1

RePEc:wkh:phecon:v:26:y:2008:i:9:p:733-744 [Citation Analysis]		1

RePEc:wkh:phecon:v:29:y:2011:i:8:p:673-685 [Citation Analysis]		1

RePEc:wkh:phecon:v:24:y:2006:i:2:p:123-139 [Citation Analysis]		1
2009Converting the SF-12 into the EQ-5D: An Empirical Comparison of Methodologies
RePEc:wkh:phecon:v:27:y:2009:i:6:p:491-505 [Citation Analysis]		1

RePEc:wkh:phecon:v:26:y:2008:i:4:p:269-280 [Citation Analysis]		1

RePEc:wkh:phecon:v:24:y:2006:i:1:p:39-41 [Citation Analysis]		1
2009Weighting Must Wait: Incorporating Equity Concerns into Cost-Effectiveness Analysis May Take Longer than Expected
RePEc:wkh:phecon:v:27:y:2009:i:12:p:983-989 [Citation Analysis]		1

Citing documents used to compute impact factor 1:
YearTitleSee
2010Valuing health technologies at nice: recommendations for improved incorporation of treatment value in HTA
RePEc:wly:hlthec:v:19:y:2010:i:10:p:1109-1116		[Citation Analysis]

Cites in year: CiY

Recent citations received in: 2010

YearTitleSee

Recent citations received in: 2009

YearTitleSee

Warning!! This is still an experimental service. The results of this service should be interpreted with care, especially in research assessment exercises. The processing of documents is automatic. There still are errors and omissions in the identification of references. We are working to improve the software to increase the accuracy of the results.

Source data used to compute the impact factor of RePEc series.
Hosted by Valencian Economic Research Institute ©2012 Jose Manuel Barrueco | mail: barrueco@uv.es